EU chemicals regulation nears final stages
This article was originally published in Clinica
The European Parliament's environment and public health committee was due to vote on the draft EU chemicals regulation, REACH, on October 4. This is the last of ten EP committees to give its opinion on the text; over 1,000 amendments by five committees were adopted in mid-September. The aim of the text is to prevent exposure to unsafe chemicals, but the European Commission has also stressed the need to safeguard the competitiveness of Europe's industry - and SMEs in particular. The final text may impact the medical device and diagnostics industry's access to materials used in the manufacture and sterilisation of its products. Rapporteur Guido Sacconi now faces the task of having to bring all the amendments together. He fears that so many changes may water down REACH's initial aims of replacing hazardous products, placing a burden of proof on industry and not overloading the future European Agency for Chemical Products. The text will begin to be debated at the Council from this week.
You may also be interested in...
Dr Reddy's is poised to expand its OTC offering in Russia and certain CIS countries by snapping up a basket of allergy brands from fellow Indian firm Glenmark.
Sandoz has launched an awareness campaign under the banner of “Ask For Generics” in the US. The initiative is aiming to educate stakeholders on the benefits of generics and their quality, safety and efficacy.
European Commission proposals for strengthening intellectual property protections in the EU, particularly the supplementary protection certificate (SPC) system, have been broadly welcomed by Europe’s brand industry. But the medical NGO, MSF, says the SPC proposals run counter to the commission’s own efforts to improve access to medicines.